| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.2 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.1 | 0.2 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |